Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Thoughts on AACR Posters -- overall, very good DELTAs.

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Apr 20, 2023 5:35pm

73 Views

Post# 35406218

RE:RE:RE:RE:RE:RE:RE:RE:Thoughts on AACR Posters -- overall, very good DELTAs.

This technical stuff is fascinating to read especially by someone who is much more familiar with Intermittent Fasting than Intermittent dosing

scarlet1967 wrote: Another aspect of intermittent dosing is it will allow other cells(healthy cells) to develop resistance. It appears tumor cells develop the resistance faster so slowing down that resistance as healthy cells catch up is the idea. The logic behind it on molecular level seems to be complicated and but the results seems to be less toxicity and better efficacy. Also as you stated the side effects might last for a while so maybe that's why they decided to enroll patients with less than 12 previous cycles so they can tolerate the side effects better than embattled patients with many previous treatments resulting in less tolerance....
qwerty22 wrote:
That's a good point but I guess we are dealing with symptoms with these toxicities. You could damage nerves over a short period of time but the symptoms persist even though the damage is not ongoing. Ongoing symptoms are not necessarily a sign of ongoing damage, they could just be from some initial damage that takes time to heal.

Anyway I'm joining speculative dots here. Strong chance I'm wrong it's just that observation jumped out at me. I've been involved in mouse model work but never cancer related, there could be technical reasons why this is happening. The problem is I've got a potential mechanism rolling around my head that would explain a short-lived drug effect. There's not enough evidence it's anything but my fantasy. We need the company to replace speculation with facts.

scarlet1967 wrote: If TH1902 indeed stop working after one or two weeks I would guess it is not because of lack of only internalizations as they did have off targeted delivery resulting in side effects so I would think the drug internalizes in both healthy and cancerous cells under constant pressure will eventually develop “acquired resistance” to the cytotoxic agents due to mutations among others. During the trial the cycles were on constant basis every 3 weeks followed by similar time period for their analysis (rest time), however they did mention in previous CPs other alternatives such as weekly and intermittent dosing. The idea about on/off or high/low dosing is the adaptive dosing may interrupt the growth of drug-dependent resistant cancerous cells which seems be an alternative route of dosing schedule for traditional chemo and I can’t see why it cannot be applied to targeted therapy. We will see whether the new dosing strategies after the restart would consider any of these.